AbstractThis research examined the potential of novel GPR40/PPARδ dual agonists, HWL‐088 and ZLY‐032, to protect the kidneys in a mouse model of adenine‐induced renal fibrosis. Mice were given a diet containing 0.25 % adenine to develop renal fibrosis and then received different dosages of HWL‐088 or ZLY‐032. After being euthanized, tissue and serum samples were collected for morphological, histological, and molecular examination. Compared to the control group, mice fed adenine showed an increase in kidney‐to‐body weight ratio, serum creatinine, and urea levels. Hematoxylin and eosin staining revealed alleviated glomerulosclerosis, tubular dilation, and inflammatory cell infiltration in mice treated with HWL‐088 or ZLY‐032. Furthermore, Masson staining and immunohistochemistry demonstrated that these dual agonists protected against renal interstitial fibrosis and inflammation, corroborated by decreased expression levels of fibrosis‐related proteins (TGF‐β, Collα1, TIMP‐1) and pro‐inflammatory cytokines (TNF‐α, IL‐1β, IL‐6). Accordingly, it can be inferred that GPR40/PPARδ dual agonists HWL‐088 and ZLY‐032 could yield significant renoprotective effects by inhibiting inflammation and fibrosis. Overall, these results may contribute to the development of novel therapeutic strategies for renal fibrosis.